Search Results

Merck today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP).

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer.

Harpoon Therapeutics, Inc. today announced that it has entered into a securities purchase agreement for a private placement in public equity (“PIPE”) financing that is expected to result in upfront gross proceeds of approximately $100 million.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today that AbbVie has notified the company that it will not exercise the exclusive license option of the parties’ Development and Option Agreement in connection with Harpoon’s HPN217 program, which targets B cell maturation antigen, or BCMA.

Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the third quarter ended September 30, 2023 and provided corporate updates.

Harpoon Therapeutics, Inc. today announced that management will participate in two upcoming investor conferences.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced that management will participate in two upcoming investor conferences in September.

Harpoon Therapeutics, Inc. today announced abstract acceptance and an upcoming rapid oral presentation of updated interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine tumor types at the American Society of Clinical Oncology Genitourinary Cancers Symposium.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Harpoon Therapeutics, Inc. announced abstract acceptance and upcoming oral presentation of the results from the completed dose escalation portion of the Phase 1 study of HPN217 in patients with relapsed/refractory multiple myeloma.